Latest Content

The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients experiencing increased skin cancer risk, highlighting the need for vigilant monitoring and innovative treatment strategies.

Predictions from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., Sarah Emond, M.P.P., Adam Kautzner, Pharm.D., David Fields, Nate Karnitz, MBA, and David Blair

New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.

GLP-1 obesity drugs saw shifting coverage and access in 2025, with low long-term adherence, payer cost concerns, new generics and key regulatory and formulary moves shaping use.

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising new and repurposed therapies for pulmonary fibrosis.

This year in type 1 diabetes, researchers advanced immune-reprogramming nanoparticle therapies and hypoimmune stem cell transplants, launched pivotal islet cell therapy trials, updated screening and treatment guidelines, and warned that cuts to research funding could slow future innovation.

Breakthrough treatments, shifting care models and persistent system challenges defined cancer care this year, from evidence that CAR T-cell therapy can lower costs and treatment burden in mantle cell lymphoma to promising off-the-shelf cancer vaccines.

This year, we explored how innovations in women's health are bridging care gaps, addressing biases and enhancing access to vital treatments and screenings.

Tylenol and autism, the Inflation Reduction Act, the One Big Beautiful Bill, Most Favored Nation pricing and direct drug sales to consumers were some of the biggest news items we covered in 2025.

Transparency, prior authorization, PBM reform and PBM offered genomics testing are some the trends Formulary Watched tracked in 2025.

Discover groundbreaking treatments for prurigo nodularis, including vixarelimab and soficitinib, offering hope for effective symptom relief and improved quality of life.

The approval comes two months after Jascayd (nerandomilast) was approved for idiopathic pulmonary fibrosis.

Sunscreen remains essential for skin health, despite recent controversies. Experts emphasize proper use and broad-spectrum protection to prevent skin cancer.

MHE has a conversation with Renuka Iyer, M.D., who became CMO of NCCN in early December. Iyer is aiming to enhance evidence-based cancer care and expand guidelines for rare cancers and diverse populations.

University of Florida researchers found immune systems destroy single beta cells before attacking larger pancreatic islets, explaining Type 1 diabetes progression and why younger patients lose cells more aggressively.

Winter exacerbates atopic dermatitis in children, but effective management strategies and new treatments offer hope for improved skin health and comfort.

Here’s what you missed this week on Managed Healthcare Executive.

Discover groundbreaking advancements in dermatology from the 2025 Fall Clinical Conference, featuring innovative treatments for psoriasis, alopecia, and atopic dermatitis.

Pfizer’s sigvotatug vedotin combined with Keytruda is being studied in patients with non-small cell lung cancer. Researchers suggest sigvotatug vedotin’s ability to induce immunogenic cell death may enhance antitumor activity.

To gain approvals, biosimilar manufacturers could do faster, less expensive analytical studies of their products' composition.

The medical director The US Oncology Network discusses adherence to clinical pathways, CAR-T therapy and concerns about the consequences of drug price negotiation under the IRA.

The Residual Transformer Generative Adversarial Network (RRTGAN) generates high-quality, cellular-level retinal images from minimal data inputs, overcoming the limitations of previous slow and burdensome imaging methods.

The findings challenge the conventional view that daytime sleepiness is always a result of insufficient sleep, poor sleep hygiene or classic sleep disorders.

In 2025, atopic dermatitis care evolved with new treatments, prioritizing holistic methods and personalized strategies for improved patient outcomes.

Researchers used nanoparticle technology to encapsulate paclitaxel and target bladder tumors more effectively. Early results demonstrate tumor elimination and minimal side effects.

Kyverna’s investigational CAR-T therapy, mivocabtagene autoleucel (miv-cel) showed clinically meaningful mobility improvements in most stiff-person syndrome patients, prompting the company to plan an FDA BLA submission in 2026.

The new radiotracer takes advantage of two biological targets linked to fibrotic and inflammatory processes in the lung: fibroblast activation protein and integrin receptors.

Falls among older adults with visual impairment are strongly linked to modifiable home hazards—especially broken flooring and tripping risks—while fall risk remains relatively low in hazard-free homes.

Trial results presented at the annual meeting of the American Society of Hematology showed decided advantages of Hympavzi (mastacimab) over on-demand treatment with bypassing agents.

Despite widespread awareness of shingles risk factors, fewer than one-third of U.S. primary care physicians are fully aware of current ACIP shingles vaccine recommendations, highlighting the need for improved education and implementation.

The top stories out of the AAD annual meeting highlight how dermatology care is evolving.